

## NPCA Newsletter, Summer 2019

### Annual Report 2019

Thank you to all members of Trust teams who collected and submitted data for this year's Annual Report. The production of the report is currently in progress by the NPCA team.

Please find enclosed a **data summary** of the final cancer registration dataset with the number of patients allocated to the Trust where the patients were diagnosed between 1 April 2017 and 31 March 2018. The table also includes the completeness of the data items describing key patient and tumour characteristics.

The **cancer registration** dataset set **can no longer be changed**, but we really need your **feedback**. It will help us to interpret the results of our analyses so that we can add an explanation in the Annual Report. **Please check the data that we have for your Trust. If you think the number of men allocated to your Trust at diagnosis is incorrect please inform the NPCA team via email [n pca@rcseng.ac.uk](mailto:n pca@rcseng.ac.uk) by Monday 22nd July 2019. Also, please let us know if the completeness of data items in your Trust is lower than expected.**

Professor Noel Clarke, NPCA Urological Lead will present the key results during the **British Association of Urological Surgeons' (BAUS) Oncology meeting 21st – 22nd November 2019** (subject to approval from NHS England).

We are working towards publication of the report and [provider-level results](#) in January 2020. We will notify you in due course when a confirmed publication date is available.

### NPCA Performance Indicators 2019

In the Annual Report 2019, the following three performance indicators will be reported for each **Specialist Multidisciplinary Team** (related to the Trust where a patient was diagnosed):

- The proportion of men with metastatic prostate cancer at diagnosis
- The proportion of men with low-risk localised prostate cancer undergoing radical prostate cancer therapy
- The proportion of men with locally advanced disease receiving radical prostate cancer therapy

The following indicator will be reported for each **Trust that provides radiotherapy**:

- The proportion of men experiencing a severe bowel complication requiring an intervention following external beam radiotherapy

## NPCA Performance Indicators (cont.)

The following two indicators will be reported for each **Trust that carries out radical prostate cancer surgery**:

- The proportion of patients who had an emergency readmission within 90 days of radical prostatectomy
- The proportion of men experiencing a severe urinary complication requiring an intervention following radical prostatectomy

Further work is in progress by the NPCA Project Team to provide comparative information on the use of hypofractionated radiotherapy, brachytherapy boost and docetaxel.

## Detection and Management of Outliers

The NPCA team has started the production of this year's Annual Report (2019). We will contact your unit in September 2019 if a **performance indicator** for your unit is **not within an acceptable range**. The steps we will follow are outlined in the [NPCA Outlier Policy for 2019](#). Please visit the NPCA website regularly and check the NPCA Outlier Policy for any updates.

## NPCA Organisational Audit 2018/19

Thank you to all Clinical Leads and Oncological Leads who responded to the NPCA Organisational Audit update. All NHS Trusts and Health Boards participated in the survey which represents the organisation of prostate cancer services at the time of data collection (December 2018 to March 2019).

A report presenting the [key diagnostic, treatment and support services available at NHS providers of prostate cancer services in England and Wales](#) is available for download from the NPCA website.

## Quality Improvement (QI): tools & activities

The NPCA provides information on the care and outcomes of men diagnosed with prostate cancer in England and Wales. The Audit determines whether the care provided by NHS hospitals meets current recommendations and also compares care outcomes among NHS hospitals.

We welcome your feedback on the [NPCA Quality Improvement Action Plan template](#) which enables teams to track progress further to evaluation of their individual results in the NPCA Annual Report 2018, the report's recommendations and suggested actions. In addition, we provide links to useful [QI resources](#) and [case studies](#) demonstrating how the results from the NPCA and the outlier process act as a driver for QI.

**Clinical Leads and Oncological Leads are invited to the first NPCA QI workshop in London on 13.12.19—please save the date!** We will be in contact directly with further information in the coming weeks.

## NPCA publications in 2019

[Imputation of missing prostate cancer stage in English cancer registry data based on clinical assumptions.](#) *Cancer Epidemiology* 2019 Feb;58:44-51.

[Impact of cancer service centralisation on the radical treatment of men with high-risk and locally advanced prostate cancer: A national cross-sectional analysis in England.](#) *International Journal of Cancer* 2019 Jul;145 (1):40-48.

[Treatment-Related Toxicity Using Prostate-Only Versus Prostate and Pelvic Lymph Node Intensity-Modulated Radiation Therapy: A National Population-Based Study.](#) *Journal of Clinical Oncology* 2019 Jun (epub): doi: 10.1200/JCO.18.02237